Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Inhalation of Environmentally Simulated PET Nanoplastics Induces Demyelinating Disorders via the CXCL12/CXCR4 Axis.
Animal models for investigating post-stroke cognitive impairment: A neurovascular trafficking perspective.
Reduced perivascular diffusion in multiple sclerosis is associated with aging, disease duration, and mobility impairment.
Characterization of distinct cognitive domain patterns in AQP4-IgG-positive NMOSD: A MoCA-based factor analysis and risk profiling.
Efficacy of nutraceuticals as adjunctive therapies in autoimmune diseases: A systematic review of clinical trials.
Rituximab versus ocrelizumab: When inference exceeds the evidence.
External validation of the MOG-AR score in pediatric myelin oligodendrocyte glycoprotein antibody-associated disease.
Pelvic Floor Knowledge, Toileting Behaviors, and Lower Urinary Tract Symptoms in Women with Multiple Sclerosis.
Therapeutic Plasma Exchange in Pediatric Patients: A Multi-Institutional Landscape Analysis.
A bioactive NGF-functionalized dermal scaffold promotes functional and morphological recovery with favorable hematological profiles after sciatic nerve injury in rats.
Microglial Ring1 enhances post-phagocytic myelin debris processing: Attenuation of cognitive dysfunction after hemorrhagic shock and reperfusion.
Polyomavirus Drives Cerebellar Lesions in AIDS Monkeys With Ataxia.
Cognitive Function and Disability in People with Multiple Sclerosis: A Systematic Review and Meta-Analysis.
Soluble TIM-3 and galectin-9 in cerebrospinal fluid are associated with disability at 6 months in aquaporin-4 IgG-positive neuromyelitis optica spectrum disorder.
Comment on "Lacosamide effects on pain management in patients with multiple sclerosis: A randomized, double-blind, placebo-controlled clinical trial".
The multiple sclerosis exposome: environmental determinants, immunological convergence, and the Gulf Region as a natural test case.
An interim analysis of acute treatment adverse events and patient reported quality of life for functional imaging guided salivary gland sparing radiation therapy using diffusion-weighted magnetic resonance imaging.
Differential Trajectories of Brain Atrophy in Multiple Sclerosis, MOGAD, and AQP4 + NMOSD: The Role of Disease Activity in MOGAD.
Endothelial neo-antigen expression initiates CD8⁺ T cell-driven CNS vasculitis amplified by peripheral immune challenge.
Betaine Attenuates Cuprizone-Induced Cortical Demyelination: The Role of the WNT4/mTOR Signalling Pathway in Regulating Astrogliosis and Synaptic Integrity.
Incident Comorbid Diabetes and Outcomes in Multiple Sclerosis: An English Population-Based Cohort Study.
Role and mechanism of ATF6-mediated endoplasmic reticulum stress in ITLN-1 against cerebral ischemia-reperfusion injury.
Neural stem cell transplantation in progressive multiple sclerosis: STEMS study long-term outcomes.
Diet and physical activity in multiple sclerosis: associations with quality of life and disability by disease duration.
Psoriasis: Which therapy for which patient, updated, part I. Focus on Psoriasis Comorbidities and Preferred Systemic Agents.
Pages
« first
‹ previous
…
1128
1129
1130
1131
1132
1133
1134
1135
1136
next ›
last »